Arrowhead Pharmaceuticals shares rise on positive interim trial resultsProactive Investors • 04/25/23
Arrowhead Pharmaceuticals' Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of EffectBusiness Wire • 04/25/23
Arrowhead: A Compelling Investment In RNAi Therapeutics With Significant Upside PotentialSeeking Alpha • 04/11/23
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to ArrowheadBusiness Wire • 04/04/23
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care ConferenceBusiness Wire • 03/03/23
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated DiseasesBusiness Wire • 02/28/23
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 ResultsBusiness Wire • 02/15/23
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary FibrosisBusiness Wire • 02/02/23
Why Arrowhead Pharmaceuticals Stock Is Diving Today - Arrowhead Pharma (NASDAQ:ARWR)Benzinga • 01/09/23
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseBusiness Wire • 01/09/23
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/21/22